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Background
The diversity of HIV-1 viruses, especially the multiplicity
of epitopes presented by the sequence variable loops of
different strains, is a major obstacle to developing a suc-
cessful vaccine.
Methods
In order to estimate the worldwide prevalence of V3
epitopes recognized by several monoclonal antibodies
(mAbs) which have been crystallographically resolved in
complex with V3 peptides bound, we used our recently
published method in which the entire LANL HIV
sequence database was searched for the occurrence of each
epitope motif recognized by selected broadly neutralizing
anti-V3 mAbs [Cardozo T et al., AIDS Res Hum Retrovi-
ruses, 2009. 25: 441]. The occurrence of these epitopes
was then corrected using updated estimates of global HIV-
1 subtype distribution [Hemelaar J et al., AIDS, 2006, 20:
W13].
Results
We estimated the epitope prevalence in worldwide HIV-1
strains for each of the epitopes recognized by the follow-
ing anti-V3 loop mAbs: 2219 (66.91%, present in all sub-
types), 3074 (82.72%, present in all subtypes), 3791
(64.25%, present primarily in non-B subtypes), 447
(12.36%, present primarily in subtype B), and 268
(3.75%, present mostly in subtype B).
Conclusion
The results illuminate the disconnect between epitope-
based classification of HIV-1 strains (described here) and
traditional genotype-based classification. Furthermore,
the results demonstrate that certain neutralizing epitopes
(e.g. that recognized by mAb 3074) are present in almost
all circulating HIV-1 strains despite their location in
sequence variable loops.
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